Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Inclusion Criteria: * Health Male Volunteers (Age : 19\~55 years) * Body Weight≥55kg, 18.5≤BMI\<25.0 Exclusion Criteria: * galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption * Allergy or Drug hypersensitivity * Clinically significant Medical History * AST, ALT \> Upper Normal Range\*1.25, eGFR\<60mL/min/1.73㎡ * Drink during clinical trial period * Smoking during clinical trial period * Grapefruit/Caffeine intake during clinical trial period * No Contraception